Cargando…

Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium

With the advent of targeted therapies there was a paradigm shift in the treatment of metastatic adenocarcinoma of lung. Immuno-histopathology and molecular subtyping in metastatic adenocarcinoma lung have enabled personalized treatment for each patient. Oncogenic driver mutations in non-small cell l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anjali, V.R., Pandey, Rambha, Srivastava, Astha, Rajeshwari, Madhu, Pandey, Durgatosh, Sharma, M.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838794/ https://www.ncbi.nlm.nih.gov/pubmed/31720204 http://dx.doi.org/10.1016/j.rmcr.2019.100954

Ejemplares similares

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Marino, Federica Zito, et al.
Publicado: (2015)

Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Zito Marino, Federica, et al.
Publicado: (2015)

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
por: Fan, Jun, et al.
Publicado: (2020)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report
por: Huang, Jie, et al.
Publicado: (2022)

Surgical management of bronchopulmonary carcinoids: A single center experience
por: Jakhetiya, Ashish, et al.
Publicado: (2017)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
por: Kim, Hyungjin, et al.
Publicado: (2019)

Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report
por: Wang, Hongbiao, et al.
Publicado: (2022)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
por: Leung, Jackson Ka Chun, et al.
Publicado: (2023)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma
por: Li, Pupu, et al.
Publicado: (2019)

Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma—a case report and a literature review
por: Cipriano, Élia, et al.
Publicado: (2021)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Decreased Tertiary Lymphoid Structures in Lung Adenocarcinomas with ALK Rearrangements
por: Zou, Yi, et al.
Publicado: (2022)

Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey
por: Sag, Sebnem Ozemri, et al.
Publicado: (2016)

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)

Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status
por: Han, Xiaoyu, et al.
Publicado: (2020)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin
por: Moatter, Samar, et al.
Publicado: (2018)

Androgen signalling in the ovaries and endometrium
por: Lissaman, Abbey C, et al.
Publicado: (2023)

TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
por: Ouseph, Madhu M, et al.
Publicado: (2019)

Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangement
por: Kawamoto, Hironori, et al.
Publicado: (2016)

Clonally‐related primary ALK rearranged adenocarcinoma and associated metastatic lesions
por: Zhu, You‐cai, et al.
Publicado: (2018)

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
por: Mori, Mio, et al.
Publicado: (2019)

Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib
por: Yokoyama, Akira, et al.
Publicado: (2018)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer
por: Lee, Kyung Ann, et al.
Publicado: (2014)

ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
por: Incharoen, Pimpin, et al.
Publicado: (2016)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
por: Hu, Haoyue, et al.
Publicado: (2023)

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
por: Tan, Xueyun, et al.
Publicado: (2022)

ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma
por: Mao, Yanjiao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5mb4acqo3gt6guehvjbqk301k0